This week on the podcast I speak with Emily English, VP of Quality at Cartesian Therapeutics.
Cartesian is a clinical-stage biopharmaceutical company developing RNA cell therapies designed to benefit the wide range of patients with cancer, autoimmune diseases, and respiratory diseases. We discussed RNA cell therapy and how Cartesian are bringing forward their mission of developing safer cell therapies for patients with autoimmune diseases. We talk about the following in detail:
- The work Cartesian are doing in RNA cell therapy and why it is exciting for patients.
- How early data suggests that Cartesian’s lead programme can provide durable therapeutic benefit to patients with autoimmune diseases.
- Why Cartesian brought manufacturing in-house, the implications and the benefits of internal manufacturing.
- The transition in thinking and managing for risk and potential downtimes in the future versus planning for success.
- The challenges of bringing autologous cell therapies to patients at scale.
- Creating scalable processes for commercialisation, ensuring sustainability, and streamlining quality processes.
- At which stage in clinical development should organisations be thinking about creating scalable processes.
- How Cartesian are changing the way traditional cell therapies are developed and the implications of these changes.
- Emily’s values, her outlook on leadership, and what inspires her.
It was a pleasure to speak with Emily. It’s hugely exciting to see the incredibly innovative work that her and the team at Cartesian are doing to help patients suffering from autoimmune diseases. I’m looking forward to seeing the progress that Emily and her team make in bringing these therapies closer to the patients as they scale in a commercial setting.
We will definitely have another conversation in 12 months time to see how things are progressing at Cartesian!
I hope you enjoy the show!